A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

References

• Berto P, D’Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 2000;1:3–10
   Google Scholar
• Hale AS. ABC of mental health: depression. Br Med J 1997;315:43–6
   PubMed Web of Science ®Google Scholar
• Angst J. The epidemiology of depressive disorders. Eur Neuropsychopharmacol 1995;5:95–8
   PubMed Web of Science ®Google Scholar
• Scott AIF, Freeman CPL. Edinburgh primary care depression study: treatment, outcome, patient satisfaction and cost after 16 weeks. Br Med J 1992;304:883–7
   PubMed Web of Science ®Google Scholar
• Thompson D, Richardson E. Current issues in the economics of depression management. Curr Psychiatry Rep 1999;1:125–34
   PubMedGoogle Scholar
• Hemels MEH, Kasper S, Walter E, Einarson TR. Cost- effectiveness analysis of escitalopram: a new SSRI in the first line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004;20:869–78
   PubMed Web of Science ®Google Scholar
• Hemels MEH, Kasper S, Walter E, Einarson TR. Cost- effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004;38:45–55
   Google Scholar
• Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 2004;30:158–66
   PubMed Web of Science ®Google Scholar
• Culpepper L. Escitalopram: a new SSRI for the treatment of depression in primary care. Prim Care Companion J Clin Psychiatry 2002;4:209–14
   PubMedGoogle Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19:305–10
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18: 211–7
   Google Scholar
• Lepola UM, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149–55
   Google Scholar
• François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002;5:91–107
   Google Scholar
• François C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003;4:12–9
   Google Scholar
• NHS National Institute for Clinical Excellence. Guidance for manufacturers and sponsors. Technology appraisals process series No 5. Available at: Http://www.nice.org.uk [accessed: 04/05/2004]
   Google Scholar
• Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for psychopharmacology guidelines. J Psychopharmacol 2000;14: 3–20
   Google Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8: 181–8
   Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(Suppl 1):29–35
   PubMedGoogle Scholar
• General Practice Research Database. GPRD analysis. Data on file H. Lunbeck A/S Paris; 2003
   Google Scholar
• Expert panel. Depression referrals to secondary care – treatment algorithm development. Cam Market Research. Data on file H. Lundbeck A/S Paris; 2002
   Google Scholar
• Data Archive. OPCS surveys of psychiatric morbidity: private household survey. Colchester, Essex; 1993
   Google Scholar
• Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38:97–111
   Google Scholar
• Leff J, Vearnals S, Brewin CR, et al. The London Depression Intervention Trial. Randomised controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: clinical outcome and costs. Br J Psychiatry 2000;177:95–100
   Google Scholar
• Department of Health. Hospital episode statistics 1999–2000. Available at http://www.nepho.org.uk [accessed: 07/06/2004]
   Google Scholar
• Meltzer H, Gill B, Petticrew M, Hinds K. OPCS surveys of psychiatric morbidity in Great Britain. Report 3: economic activity and social functioning of adults with psychiatric disorders. London: OPCS; 1995
   Google Scholar
• Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001;4:113–8
   PubMed Web of Science ®Google Scholar
• O’Donoghue J, Goulding L, Allen G. Consumer price inflation since 1750. Economic trends (Report No. 604). National Office for Statistics; 2004
   Google Scholar
• Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. Canterbury: University of Kent; 2001
   Google Scholar
• Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer’s perspective: a multinational study. Int J Clin Pract 2001;55:292–9
   PubMed Web of Science ®Google Scholar
• Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost- effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16–31
   PubMedGoogle Scholar
• Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000;18:143–8
   Google Scholar
• Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665–73
   Google Scholar
• Lenox-Smith A, Conway P, Knight C. Cost-effectiveness of representatives of three classes of antidepressants used in major depressive disorder in the UK. Pharmacoeconomics 2004; 22:311–9
   Google Scholar
• Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 1996;168:768–71
   Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44–9
   Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in patients in primary care with major depressive disorder. Neuropsychobiology 2004;50:57–6
   Google Scholar
• Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment- resistant patients. J Clin Psychiatry 2001;62:135–42
   PubMed Web of Science ®Google Scholar
• National Health Service England and Wales. Drug Tariff Q4 2003. London: Prescription Pricing Authority; 2004
   Google Scholar
• Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000;15:378–87
   PubMed Web of Science ®Google Scholar